Document Detail


Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy.
MedLine Citation:
PMID:  20155987     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Edaravone is a free-radical scavenger that has been widely used for acute ischaemic stroke in Japan. However, the optimal total dosage of edaravone has not been established. OBJECTIVE: To clarify the relationship between the gain in functional recovery (rehabilitation gain) and the total amount of edaravone used for acute-phase therapy for cerebral infarction at a convalescent rehabilitation hospital. We also sought to determine if there were differences in outcome between stroke subtypes. METHODS: Medical records were retrospectively surveyed to identify patients who had received edaravone treatment for acute-phase cerebral infarction at Kawakita General Hospital, Tokyo, Japan, followed by recovery rehabilitation at Kawakita Rehabilitation Hospital, Tokyo, Japan, for > or = 30 days. Edaravone was initiated within 24 hours of stroke onset, and was administered as a 30 mg (1 ampoule) continuous intravenous infusion twice daily for up to 14 days. Patients were stratified into tertiles based on the total amount of edaravone used (measured in ampoules) during the acute phase (i.e. administration duration). Rehabilitation gain was defined as the change (increase) from convalescent rehabilitation hospital admission to discharge in the Functional Independence Measure-Motor (DeltaFIM-M) or Barthel Index (DeltaBI) score. RESULTS: Of the 72 enrolled patients, 21 belonged to the lower (short-term) tertile (0-14 ampoules), 27 to the middle (medium-term) tertile (15-23 ampoules) and 24 to the upper (long-term) tertile (24-33 ampoules) groups. There was no correlation between the total amount of edaravone used and the length of stay at an acute-phase hospital. However, a significant correlation was seen between the total amount of edaravone used and DeltaFIM-M (adjusted regression coefficient 0.81; p = 0.003) and DeltaBI (0.88; p = 0.005) score in patients with cardioembolic stroke; no significant correlation was seen in other stroke subtypes. Cardioembolic stroke patients also showed improvements in both FIM-M and BI score as the total amount of edaravone used increased. The difference between the short- and long-term group was 10.1 (95% CI 2.3, 17.8) for DeltaFIM-M score, and 12.0 (95% CI 2.8, 21.2) for DeltaBI score. Patients with atherothrombotic stroke showed a similar tendency with respect to DeltaBI score. CONCLUSION: Edaravone dose-dependently increases rehabilitation gain according to DeltaFIM-M and DeltaBI scores in patients with cardioembolic stroke, and a similar trend was also observed with respect to DeltaBI score in patients with atherothrombotic stroke. This suggests that the total amount of edaravone used is associated with its efficacy for rehabilitation gain.
Authors:
Yoshiko Unno; Makiko Katayama; Hideaki Shimizu
Related Documents :
22323847 - Overlay versus underlay myringoplasty: report of outcomes considering closure of perfor...
14671247 - Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent...
17885237 - Preprocedural c-reactive protein levels predict stroke and death in patients undergoing...
1572847 - Wound bed preparation: approaches to replacement of dermis.
19551547 - The efficacy and safety of percutaneous microwave coagulation by a new microwave delive...
11330387 - Achalasia: the case for primary laparoscopic treatment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  30     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2010  
Date Detail:
Created Date:  2010-02-16     Completed Date:  2010-05-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  143-55     Citation Subset:  IM    
Affiliation:
Department of Neurology, Kawakita General Hospital, Tokyo, Japan. yoshiko@med.kitasato-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antipyrine / analogs & derivatives*,  therapeutic use
Cerebral Infarction / diagnosis,  drug therapy*,  rehabilitation
Dose-Response Relationship, Drug
Free Radical Scavengers / therapeutic use*
Humans
Japan
Length of Stay / statistics & numerical data
Recovery of Function / drug effects*
Rehabilitation Centers
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Free Radical Scavengers; 60-80-0/Antipyrine; 89-25-8/phenylmethylpyrazolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Binding of Functionalized Paramagnetic Nanoparticles to Bacterial Lipopolysaccharides And DNA.
Next Document:  Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia: The ESSENTIAL Study.